RxDoctor Payments Data

Meghan Pollard

Nurse Practitioner · Newport News, VANPI 1790338531

Payments from drug & device makers

$3,221in general payments, 2019–2025

Across 52 payments — averaging $61.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$395
  • AstraZeneca$373
  • Amgen$344
  • Lilly USA, LLC$277
  • Biohaven Pharmaceutical Holding Company Ltd.$254
  • AbbVie$240
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,221100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,221 in reported general payments places this provider in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$135,010
Medicare patients
194
Services billed
3,678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban46$41,407
TrulicityDulaglutide25$27,594
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$18,242
XareltoRivaroxaban14$17,740
MultaqDronedarone Hcl12$9,908
FarxigaDapagliflozin Propanediol12$7,047
Tresiba Flextouch U-100Insulin Degludec11$4,322
Duloxetine Hcl47$2,573
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,507
Celecoxib15$1,162
Pantoprazole Sodium60$1,131
Atorvastatin Calcium135$1,043
Pregabalin22$867
Nifedipine ErNifedipine12$722
Levothyroxine Sodium65$594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$41,40746 claims
Lilly USA, LLCTrulicity$277$27,59425 claims
GSKTrelegy Ellipta$55$18,24227 claims
AstraZenecaFarxiga$373$7,04712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →